SpyGlass Surgical Study
Completed · NCT05822635
Conditions: Pancreatic Diseases, Bile Duct Diseases, Hepatic Disease
At a glance
- Research payments reported, 2025
- $13,720
- U.S. investigators named
- 2
- Sites paid
- 2
- Planned or actual enrollment
- 34
About the trial
- Sponsor
- Boston Scientific Corporation
- Tested
- SpyGlass Discover Digital System or SpyGlass DS Direct Visualization System (device)
- Dates
- Started 2023-12-01; completion 2025-01-03
- Results posted
- Not yet
* To document the clinical utility of diagnostic and/or therapeutic intraoperative endoscopy using a thin, single-use, flexible cholangiopancreatoscope * To identify specific surgical procedures in which intraoperative use of a thin, single use, flexible cholangiopancreatoscope suggests clinically meaningful benefit and generate a hypothesis for possible subsequent claims-supportive study
From ClinicalTrials.gov, last updated 2025-01-08. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Boston Scientific Corporation reported $13,720 in research payments for this study in 2025 (6 payments).
Products named: Clinical Trial Product
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Christian M. Schmidt, MD General Surgery · Indianapolis, IN
- Michael L. Kendrick, M.D. General Surgery · Rochester, MN
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- The Trustees of Indiana University $8,482
- Mayo Clinic $5,238
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.